Table 5.
Comparison of baseline characteristics between groups
| mild/moderate | severe/critical | P value | ||
|---|---|---|---|---|
| (n = 55) | (n = 10) | |||
| Age, years, median (range) | 53 (19–74) | 64 (27–74) | 0.0252 | |
| ≧ 60, n (%) | 20 (36) | 7 (70) | 0.0788 | |
| Gender, n (%) | Male | 34 (62) | 4 (40) | 0.2968 |
| Female | 21 (38) | 6 (60) | ||
| DM, n (%) | 12 (22) | 7 (70) | 0.0047 | |
| HT, n (%) | 44 (80) | 10 (100) | 0.1930 | |
| BMI, kg/m2, median (range) | 22 (16.8–29.6) | 22.25 (18.8–31.8) | 0.3877 | |
| > 25, n (%) | 6 (11) | 4 (40) | 0.0393 | |
| Use of MMF as maintenance immunosuppression, n (%) | 34 (62) | 8 (80) | 0.4736 | |
|
Time from symptom onset to initial antiviral treatment, days, median (range) |
1 (0–11) | 3 (1–14) | 0.0026 | |
| Baseline eGFR, ml/min/1.73m2, median (range) | 46 (19.2–99.5) | 39 (18.3–73.5) | 0.3538 | |
| < 30, n (%) | 6 (11) | 3 (30) | 0.1345 | |
| Previous SARS-CoV-2 vaccine, doses, median (range) | 4 (0–6) | 4 (3–5) | 0.4519 |